News for Xtant Medical Holdings (XTNTW)

Total Revenue: $32.9 million, an 18% increase from the same period in 2024.Gross Margin: 61.5%, slightly down from 62.1% in the same period in 2024.Operating E

May 12, 2025 / 08:30PM GMTOperator Good afternoon, everyone, and welcome to the Xtant Medical's first quarter 2025 financial results. (Operator Instructions) Pl

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ETCompany ParticipantsBrett Maas - Hayden IRSean Browne -...

Xtant Medical (XTNT) has submitted a filing to offer 73.11 million shares of its common stock. This move is intended for current shareholders, impacting the ove

Revenue: $32.9 million, surpassing the estimated $31.20 million and marking an 18% increase year-over-year.Net Income: Achieved positive net income of $58,000,

Xtant Medical (XTNT) reports 18% revenue growth in Q1 2025, reaching $32.9 million. Achieves a positive net income of $58,000, reversing a $4.4 million

Xtant Medical Holdings Inc (XTNT) is set to release its Q1 2025 earnings on May 12, 2025. The consensus estimate for Q1 2025 revenue is $31.20 million, and the

PR NewswireBELGRADE, Mont., May 6, 2025 BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical t

Xtant Medical (XTNT) to release Q1 2025 financial results on May 12, 2025, after market close. Conference call scheduled for 4:30 PM ET on the same day,

PR NewswireBELGRADE, Mont., April 23, 2025 BELGRADE, Mont., April 23, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc.(NYSE American:XTNT), a global medic

Xtant Medical Holdings (XTNT) launches Triviumâ„¢, a next-gen bone graft with PureLocâ„¢ Fiber Technology. Triviumâ„¢ enhances surgical precision and ti

\n\nPR NewswireBELGRADE, Mont., April 16, 2025\n\n\n\nHealthcare Focused Long-term Investors Support Strategic VisionAccelerating Shift to Higher-Margin Orthobiologic

Orthofix Medical Inc. (OFIX) has reported a significant uptick in revenue for the first quarter of 2025, marking an 18% to 19% increase compared to the same per

\n Xtant Medical (XTNT) announces 18-19% expected revenue growth in Q1 2025. OrbiMed completes secondary sale of 73.1 million shares, enhan

Fourth Quarter Revenue: $31.5 million, a 12% increase from the same period in 2023.Full Year Revenue: $117.3 million, a 28% increase from 2023.Biologics Produc

Mar 06, 2025 / 09:30PM GMTOperator Good day, everyone, and welcome to the Xtant Medical fourth-quarter and year-end 2024 earnings. (Operator Intructions) It is

Full Year 2024 Revenue Growth of 28%Expects 2025 Revenue of $126 Million to $130 Million Without Need for Additional Capital BELGRADE, MT / ACCESS Newswire / Ma

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q4 2024 Results Conference Call March 6, 2025 4:30 PM ETCompany ParticipantsBrett Maas - Hayden IRSean Browne -...

Xtant Medical Holdings Inc (XTNT) is set to release its Q4 2024 earnings on March 6, 2025. The consensus estimate for Q4 2024 revenue is $31.80 million, and the